Sargramostim for Myeloid Dendritic Cell Deficiency

Exclusion Criteria

• •Age\<18or\>80years
• •History of non-adherence to prescribed HD treatment
• •Active drug or heavy alcohol use (defined as \> 4 drinks/day)
• •Pregnancy or breast feeding
• •Active infection (bacterial or viral) or clinically significant infections within the past three months (e.g. those requiring hospitalization, or as judged by the PI)
• •Active malignancy (with the exception of excised non-metastatic basal cell carcinoma or squamous cell carcinoma of the skin, or adequately treated pre- invasive cervical cancer in situ)
• •Unstable cardiovascular status (angina, arrhythmias, congestive heart failure etc...)
• •History of liver disease (as defined by a diagnosis of uncompensated cirrhosis) • History of lung disease (including moderate-severe chronic obstructive pulmonary disease, interstitial lung disease, or asthma)
• •Known hypersensitivity to yeast-derived products
• •Hemoglobin \< 10 g/dL and hematocrit \< 30%.
• •Abnormal white blood cell (WBC) count at baseline (\< 3 or \> 12 x 10 cells/mm )
• •Treatment with WBC growth factors (G-CSF or GM-CSF) or immunosuppressive medications (tacrolimus, cyclosporine, mycophenolate, azathioprine, corticosteroids, chlorambucil, cyclophosphamide) within 4 weeks of study (erythropoiesis-stimulating agents will be allowed)
• •Treatment with lithium within 4 weeks of study